1. Generics Bulletin
  2. >>Products
  3. >>Biosimilars

Bio-Thera Strengthens Ties With Pharmapark By Adding Ustekinumab

Follows Earlier License And Supply Agreement For Golimumab Biosimilar

 
• By Dean Rudge

Deal-happy Bio-Thera Solutions has signed another license and supply agreement, agreeing to out-license its BAT2206 biosimilar ustekinumab candidate in Russia and other CIS countries to local player Pharmapark.

Russia
Bio-Thera has signed another deal for its Stelara biosimilar • Source: Shutterstock

Bio-Thera Solutions Ltd. has broadened its relationship with Russia’s Pharmapark while expanding the potential geographic reach of its proposed biosimilar to Janssen’s Stelara (ustekinumab), reaching license and supply agreements with Pharmapark for the Chinese player’s BAT2206 biosimilar ustekinumab candidate in Russia and other Commonwealth of International States countries.

Under the latest partnership agreement, Pharmapark will have exclusive rights to distribute and market the drug with a status of a local product in the territories. “This partnership will leverage Pharmapark’s strong local presence, sales and marketing capabilities in Russia and other CIS countries,” the firms noted

More from Biosimilars

Cutting Out The Middlemen? Trump’s Pricing Order Offers Opportunity On PBMs

 
• By Dave Wallace

Donald Trump’s executive order on most-favored-nation prescription drug pricing could provide positive opportunities for the off-patent industry, although US generics and biosimilars association the AAM suggested that the administration might do more good by focusing elsewhere.

Amneal Proud To Be ‘Made In America’ And Ready To Scale Up Its US Manufacturing

 
• By Urtė Fultinavičiūtė

Amneal has set itself apart from competitors who are scrambling to find alternatives if proposed US pharmaceutical tariffs come into place. For the New Jersey-based firm, this is an opportunity to embrace its American identity and open a new chapter of growth.

‘I’ll Be Happy When We Have 40-Plus Assets’ – Sandoz Builds Up Biosimilars

 
• By Dave Wallace

With biosimilars playing an increasingly important role in Sandoz’s business, the firm’s first-quarter results call saw management lay out the latest key developments. Meanwhile, the company also addressed the issue of US tariffs, voicing optimism over both future developments as well as its ability to weather current measures.

Fresenius Kabi Lauds Tocilizumab Momentum As ‘Intense’ Transfer To mAbxience Continues

 
• By Dean Rudge

Fresenius Kabi continued to reap the rewards of its fledgling commercial Biopharma business in the first quarter, as the firm eyes further growth for its tocilizumab biosimilar in the US and Europe in the second half of 2025.

More from Products

Amneal Proud To Be ‘Made In America’ And Ready To Scale Up Its US Manufacturing

 
• By Urtė Fultinavičiūtė

Amneal has set itself apart from competitors who are scrambling to find alternatives if proposed US pharmaceutical tariffs come into place. For the New Jersey-based firm, this is an opportunity to embrace its American identity and open a new chapter of growth.

‘I’ll Be Happy When We Have 40-Plus Assets’ – Sandoz Builds Up Biosimilars

 
• By Dave Wallace

With biosimilars playing an increasingly important role in Sandoz’s business, the firm’s first-quarter results call saw management lay out the latest key developments. Meanwhile, the company also addressed the issue of US tariffs, voicing optimism over both future developments as well as its ability to weather current measures.

Tetris Deal Falls Into Place For UK’s Aspire

 
• By Dave Wallace

Niche generics company Aspire Pharma has struck a deal to acquire a portfolio of products from fellow UK firm Tetris Pharma as it is wound up, paying Tetris parent Arecor £0.5m for UK distribution rights and inventory.